Michael Duruisseaux, Physician-Scientist in the Onco-Pharmacology team at the Lyon Cancer Research Center, shared an article by Alison M. Schram, et al. on X:
“Hot of the press NEJM: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer | New England Journal of Medicine.
First effective targeted therapy in NRG1-fusion + solid tumors.
Very proud to collaborate to this study.”
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer.
Authors: Alison M. Schram, et al.
